140 related articles for article (PubMed ID: 36495861)
1. Toward defining the clinically actionable genome of metastatic breast cancer.
Fröhling S
Med; 2022 Dec; 3(12):818-819. PubMed ID: 36495861
[TBL] [Abstract][Full Text] [Related]
2. Implementing precision cancer medicine in the genomic era.
Chen HZ; Bonneville R; Roychowdhury S
Semin Cancer Biol; 2019 Apr; 55():16-27. PubMed ID: 29857039
[TBL] [Abstract][Full Text] [Related]
3. Next-Generation Sequencing for Advanced Breast Cancer: What the Way to Go?
Trapani D; Crimini E; Sandoval J; Curigliano G
Cancer Treat Res; 2023; 188():343-351. PubMed ID: 38175352
[TBL] [Abstract][Full Text] [Related]
4. Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology.
Tao JJ; Schram AM; Hyman DM
Annu Rev Med; 2018 Jan; 69():319-331. PubMed ID: 29120700
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
[TBL] [Abstract][Full Text] [Related]
6. Physician interpretation of genomic test results and treatment selection.
Brusco LL; Wathoo C; Mills Shaw KR; Holla VR; Bailey AM; Johnson AM; Khotskaya YB; Litzenburger BC; Sanchez NS; Zeng J; Bernstam EV; Eng C; Kee BK; Amaria RN; Routbort MJ; Mills GB; Mendelsohn J; Meric-Bernstam F
Cancer; 2018 Mar; 124(5):966-972. PubMed ID: 29165790
[TBL] [Abstract][Full Text] [Related]
7. Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience.
Repetto M; Crimini E; Boscolo Bielo L; Guerini-Rocco E; Ascione L; Bonfanti A; Zanzottera C; Mazzarella L; Ranghiero A; Belli C; Criscitiello C; Esposito A; Barberis MCP; Curigliano G
Eur J Cancer; 2023 Apr; 183():79-89. PubMed ID: 36801623
[TBL] [Abstract][Full Text] [Related]
8. Genomics to select treatment for patients with metastatic breast cancer.
Andre F; Filleron T; Kamal M; Mosele F; Arnedos M; Dalenc F; Sablin MP; Campone M; Bonnefoi H; Lefeuvre-Plesse C; Jacot W; Coussy F; Ferrero JM; Emile G; Mouret-Reynier MA; Thery JC; Isambert N; Mege A; Barthelemy P; You B; Hajjaji N; Lacroix L; Rouleau E; Tran-Dien A; Boyault S; Attignon V; Gestraud P; Servant N; Le Tourneau C; Cherif LL; Soubeyran I; Montemurro F; Morel A; Lusque A; Jimenez M; Jacquet A; Gonçalves A; Bachelot T; Bieche I
Nature; 2022 Oct; 610(7931):343-348. PubMed ID: 36071165
[TBL] [Abstract][Full Text] [Related]
9. Changing Landscape of Clinical-Genomic Oncology Practice.
Trivedi H; Kling HM; Treece T; Audeh W; Srkalovic G
Acta Med Acad; 2019 Apr; 48(1):6-17. PubMed ID: 31264429
[TBL] [Abstract][Full Text] [Related]
10. PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment.
Thouvenin J; Van Marcke C; Decoster L; Raicevic G; Punie K; Vandenbulcke M; Salgado R; Van Valckenborgh E; Maes B; Joris S; Steichel DV; Vranken K; Jacobs S; Dedeurwaerdere F; Martens G; Devos H; Duhoux FP; Rasschaert M; Pauwels P; Geboes K; Collignon J; Tejpar S; Canon JL; Peeters M; Rutten A; Van de Mooter T; Vermeij J; Schrijvers D; Demey W; Lybaert W; Van Huysse J; Mebis J; Awada A; Claes KBM; Hebrant A; Van der Meulen J; Delafontaine B; Bempt IV; Maetens J; de Hemptinne M; Rottey S; Aftimos P; De Grève J
ESMO Open; 2022 Aug; 7(4):100524. PubMed ID: 35970014
[TBL] [Abstract][Full Text] [Related]
11. Precision oncology based on omics data: The NCT Heidelberg experience.
Horak P; Klink B; Heining C; Gröschel S; Hutter B; Fröhlich M; Uhrig S; Hübschmann D; Schlesner M; Eils R; Richter D; Pfütze K; Geörg C; Meißburger B; Wolf S; Schulz A; Penzel R; Herpel E; Kirchner M; Lier A; Endris V; Singer S; Schirmacher P; Weichert W; Stenzinger A; Schlenk RF; Schröck E; Brors B; von Kalle C; Glimm H; Fröhling S
Int J Cancer; 2017 Sep; 141(5):877-886. PubMed ID: 28597939
[TBL] [Abstract][Full Text] [Related]
12. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.
Radovich M; Kiel PJ; Nance SM; Niland EE; Parsley ME; Ferguson ME; Jiang G; Ammakkanavar NR; Einhorn LH; Cheng L; Nassiri M; Davidson DD; Rushing DA; Loehrer PJ; Pili R; Hanna N; Callaghan JT; Skaar TC; Helft PR; Shahda S; O'Neil BH; Schneider BP
Oncotarget; 2016 Aug; 7(35):56491-56500. PubMed ID: 27447854
[TBL] [Abstract][Full Text] [Related]
13. From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards.
Perera-Bel J; Hutter B; Heining C; Bleckmann A; Fröhlich M; Fröhling S; Glimm H; Brors B; Beißbarth T
Genome Med; 2018 Mar; 10(1):18. PubMed ID: 29544535
[TBL] [Abstract][Full Text] [Related]
14. Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology.
Martin-Romano P; Mezquita L; Hollebecque A; Lacroix L; Rouleau E; Gazzah A; Bahleda R; Planchard D; Varga A; Baldini C; Postel-Vinay S; Friboulet L; Loriot Y; Verlingue L; Geraud A; Camus MN; Nicotra C; Soria JC; André F; Besse B; Massard C; Italiano A
JCO Precis Oncol; 2022 Oct; 6():e2100484. PubMed ID: 36315916
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.
Moreira A; Masliah-Planchon J; Callens C; Vacher S; Lecerf C; Frelaut M; Borcoman E; Torossian N; Ricci F; Hescot S; Sablin MP; Tresca P; Loirat D; Melaabi S; Trabelsi-Grati O; Pierron G; Gentien D; Bernard V; Vincent Salomon A; Servant N; Bieche I; Le Tourneau C; Kamal M
Eur J Cancer; 2019 Nov; 121():202-209. PubMed ID: 31593830
[TBL] [Abstract][Full Text] [Related]
16. Measuring Progress in Precision Oncology.
Horak P; Fröhling S
Cancer Discov; 2024 Jan; 14(1):18-19. PubMed ID: 38213297
[TBL] [Abstract][Full Text] [Related]
17. CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer.
Hlevnjak M; Schulze M; Elgaafary S; Fremd C; Michel L; Beck K; Pfütze K; Richter D; Wolf S; Horak P; Kreutzfeldt S; Pixberg C; Hutter B; Ishaque N; Hirsch S; Gieldon L; Stenzinger A; Springfeld C; Smetanay K; Seitz J; Mavratzas A; Brors B; Kirsten R; Schuetz F; Fröhling S; Sinn HP; Jäger D; Thewes V; Zapatka M; Lichter P; Schneeweiss A
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036222
[TBL] [Abstract][Full Text] [Related]
18. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory.
Arango NP; Brusco L; Mills Shaw KR; Chen K; Eterovic AK; Holla V; Johnson A; Litzenburger B; Khotskaya YB; Sanchez N; Bailey A; Zheng X; Horombe C; Kopetz S; Farhangfar CJ; Routbort M; Broaddus R; Bernstam EV; Mendelsohn J; Mills GB; Meric-Bernstam F
Oncotarget; 2017 Jun; 8(26):41806-41814. PubMed ID: 28415679
[TBL] [Abstract][Full Text] [Related]
19. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
Vasan N; Yelensky R; Wang K; Moulder S; Dzimitrowicz H; Avritscher R; Wang B; Wu Y; Cronin MT; Palmer G; Symmans WF; Miller VA; Stephens P; Pusztai L
Oncologist; 2014 May; 19(5):453-8. PubMed ID: 24710307
[TBL] [Abstract][Full Text] [Related]
20. Clinical target sequencing for precision medicine of breast cancer.
Tsuchida J; Rothman J; McDonald KA; Nagahashi M; Takabe K; Wakai T
Int J Clin Oncol; 2019 Feb; 24(2):131-140. PubMed ID: 30604156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]